LBRX screens as attractively valued with 17% analyst-implied upside, but a failed asymmetry gate, a weak Piotroski score, an overbought technical setup, and a two-quarter earnings miss streak argue the upside is not yet earned.
Thesis pillars
- Attractive Valuation Upside↓Deteriorating
- Earnings Miss Pattern↑Improving
- Weak Fundamentals Quality Floor→Stable
- +2 more pillars — see the Why tab for full reasoning
LB Pharmaceuticals Inc (LBRX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.50: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 18%; Elevated put/call ratio: 7.75; Below-average business quality.
LB Pharmaceuticals is a late-stage biopharmaceutical company developing LB-102, a novel benzamide antipsychotic and methylated derivative of amisulpride, for schizophrenia, bipolar depression and adjunctive major depressive disorder. The company initiated a Phase 3 trial in... Read more
Sell if holding. Engine safety override at $35.50: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 18%; Elevated put/call ratio: 7.75; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 5.2/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, earnings proximity 19d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About LB Pharmaceuticals Inc
About LB Pharmaceuticals Inc
LB Pharmaceuticals has no approved products and is advancing its sole clinical asset, LB-102, a benzamide antipsychotic derived from amisulpride, through a Phase 3 trial in schizophrenia initiated in March 2026 following positive Phase 2 results announced in January 2025. The company reported a $25.2 million net loss for 2025 and held $295.2 million in cash, cash equivalents and marketable securities as of December 31, 2025, targeting topline Phase 3 data in the second half of 2027.
LB-102 is designed to improve on amisulpride, a second-generation antipsychotic approved in more than 50 countries but never in the United States because its regulatory and patent-protection requirements were incompatible; LB-102 is a new chemical entity with its own composition-of-matter patent protection. Beyond the ongoing Phase 3 schizophrenia trial (NOVA-2, roughly 460 patients across 25 U.S. sites), LB Pharmaceuticals initiated a Phase 2 trial in bipolar 1 depression in January 2026 and plans a Phase 2 adjunctive major depressive disorder trial in early 2027, leveraging LB-102's antagonism of D2, D3 and 5HT7 receptors. The company also is developing a long-acting injectable formulation. LB Pharmaceuticals retains global commercialization rights to LB-102 and intends to keep U.S. rights while evaluating ex-U.S. collaborations, and owes certain co-founders and executives royalties of up to 2.75% of worldwide net sales through 2035.
Show full overview
LB Pharmaceuticals' entire value rests on a single compound tested in a field the company itself flags as unusually difficult: neuropsychiatric trials rely on subjective, patient-reported endpoints like the PANSS scale and are prone to high placebo response, a dynamic the 10-K notes has sunk other programs, including Cerevel's emraclidine in schizophrenia. If the ongoing NOVA-2 Phase 3 trial does not replicate the Phase 2 signal, LB Pharmaceuticals has no second clinical-stage asset to fall back on, and its bipolar depression and adjunctive MDD programs -- reading out in 2028 and 2029, respectively -- would carry the same underlying LB-102 risk rather than diversifying it away.
See also: Healthcare · Biotechnology
From LB Pharmaceuticals Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-25Recent Developments — LB Pharmaceuticals Inc
Latest news
- NEWS LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Sc — benzinga Jul 22, 2026 neutral
- NEWS BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46 — benzinga Jul 21, 2026 positive
- NEWS Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45 — benzinga Jul 7, 2026 positive
Generated 2026-07-25T14:18:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineLB-10210-K Item 1: 'Our lead product candidate, LB‑102, is a Phase 3 oral small molecule in development for the treatment of schizophrenia.'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02MEDIUMChief Medical Officer Anna Eramo, M.D. resigned effective June 15, 2026, for personal reasons, transitioning to an advisor and consulting role through September 15, 2026. The company said her departure is not related to clinical program operations and does not expect a material impact on clinical development activities; a search for her replacement is underway.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.50: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 18%; Elevated put/call ratio: 7.75; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $32.56. Score 5.2/10, moderate confidence.
Take-profit target: $39.91 (+14.0% upside). Prior stop was $32.56. Stop-loss: $32.56.
Concentration risk — Pipeline: LB-102; Quality below floor (2.0 < 4.0).
LB Pharmaceuticals Inc trades at a P/E of N/A (forward -8.2). TrendMatrix value score: 6.0/10. Verdict: Sell.
13 analysts cover LBRX with a consensus score of 4.2/5. Average price target: $46.
What does LB Pharmaceuticals Inc do?LB Pharmaceuticals is a late-stage biopharmaceutical company developing LB-102, a novel benzamide antipsychotic and...
LB Pharmaceuticals is a late-stage biopharmaceutical company developing LB-102, a novel benzamide antipsychotic and methylated derivative of amisulpride, for schizophrenia, bipolar depression and adjunctive major depressive disorder. The company initiated a Phase 3 trial in schizophrenia in March 2026 following positive Phase 2 results, has no approved products or product revenue, and reported a $25.2 million net loss for 2025 with $295.2 million in cash, cash equivalents and marketable securities.